(Q86403207)
Statements
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial (English)
German Hodgkin Study Group
Karolin Behringer
Helen Goergen
Felicitas Hitz
Josée M Zijlstra
Richard Greil
Jana Markova
Stephanie Sasse
Michael Fuchs
Max S Topp
Martin Soekler
Stephan Mathas
Julia Meissner
Martin Wilhelm
Peter Koch
Hans-Walter Lindemann
Enrico Schalk
Robert Semrau
Jan Kriz
Tom Vieler
Martin Bentz
Elisabeth Lange
Rolf Mahlberg
Andre Hassler
Martin Vogelhuber
Dennis Hahn
Jörg Mezger
Nicole Skoetz
Boris Böll
Bastian von Tresckow
Volker Diehl
Michael Hallek
Peter Borchmann
Harald Stein
Hans Eich
Andreas Engert
Swiss Group for Clinical Cancer Research
Arbeitsgemeinschaft Medikamentöse Tumortherapie
22 December 2014